Gene editing, a set of techniques used to alter sections of an organism's DNA, is helping scientists cure diseases previously ...
Cambridge, Massachusetts Wednesday, March 4, 2026, 18:00 Hrs [IST] ...
Using prime editing, NCF1 mutation is corrected in a 19-year-old with chronic granulomatous disease, an inherited immune ...
DelveInsight's Orphan Drugs Market Insights report provides the current and forecast market analysis, individual leading ...
The orphan drugs market is seeing strong expansion, propelled by the growing worldwide incidence of genetic conditions and other rare diseases, as well as the substantial unmet need for effective ...
The drug was finally approved in September 2025 through the FDA’s accelerated approval pathway, based on improvement in knee ...
NEW YORK – T-Knife Therapeutics plans to begin a clinical trial this year of its PRAME-targeting armored T cell receptor (TCR) therapy, after the company confirmed on Tuesday that the European ...
Researchers at the Peter Doherty Institute for Infection and Immunity (Doherty Institute) have developed a world-first ...
The FDA has outlined a proposed approval pathway for customized drugs and gene-editing therapies designed for rare and ...
Gene editing refers to the precise alteration of an organism's DNA sequence at a specific locus. In cancer treatment, this technology is leveraged to modify the genetic makeup of cancer cells, either ...
This important work identifies phlda2 as a specific marker for primordial cardiomyocytes in the adult zebrafish heart and demonstrates their essential role in myocardial morphogenesis and coronary ...
The planned filing comes amid heightened scrutiny of the FDA’s rare disease stance and a year after Prime deprioritized the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results